NCT05944445

The Incidence of Linezolid-induced Thrombocytopenia (LIT) in Critically Ill Patients, the Risk Factors for LIT

The Incidence of Linezolid-induced Thrombocytopenia (LIT) in Critically Ill Patients, the Risk Factors for LIT and Time to Events (LIT, Recovery)

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 310 (estimated)
• Sponsor: Helwan University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

* To identify the incidence of LIT among critically ill patients, as limited studies have only addressed this population. * To evaluate the impact of several factors on the incidence of LIT, the time to onset of LIT, and the time to recovery of platelets. * To study the effect of concurrent medications (enoxaparin, unfractinated heparin, piperacillin, carbapenems, tigecycline, fluconazole or voriconazole, digoxin, amiodarone, acetaminophen, tirofiban, statins, and antiepileptics) frequently used in critically ill patients on the incidence of LIT. * To investigate the impact of possible medications with an antioxidant effect on the prevention of LIT. * To assess the impact of LIT on composite end point (mortality, bleeding, and length of stay)

Conditions

• Thrombocytopenia; Drugs

Interventions

Type	Name	Description
DRUG	Linezolid 600 mg	Linezolid 600mg injection

Timeline

• Start date: 2023-07-13
• Primary completion: 2024-08-01
• Completion: 2024-08-01
• First posted: 2023-07-13
• Last updated: 2023-07-17

Locations

1 site across 1 country: Egypt

Regulatory

• FDA-regulated drug study